Radiotherapy for prostate cancer: DISCERN quality assessment of patient-oriented websites in 2018 by Janssen, S. et al.
RESEARCH ARTICLE Open Access
Radiotherapy for prostate cancer: DISCERN
quality assessment of patient-oriented
websites in 2018
S. Janssen1,4*†, F. B. Fahlbusch2†, L. Käsmann1, D. Rades1 and D. Vordermark3
Abstract
Background: Prostate cancer is the most commonly diagnosed cancer in men. Radiotherapy represents one major
treatment option in different therapeutic settings. As patients increasingly rely on internet-based medical information, we
examined the quality of information on radiotherapy and prostate cancer in websites used by laypersons.
Methods: An Internet search from a patients` perspective was carried out using different search engines (Google, Yahoo
and Bing, search terms: “prostate cancer” and “radiotherapy”). The quality of search results was analyzed with regard to
the DISCERN score, HON code certification, the JAMA criteria and the ALEXA traffic rank.
Results: In general, websites were of good quality. The highest quality was found for websites operated by charity
organizations. No significant differences in results obtained via the above-mentioned tools were seen for the examined
search engines, but Google revealed the most stable search results in terms of temporal changes.
Conclusion: Patients with prostate cancer can sufficiently inform themselves on general treatment options including
radiotherapy on websites directed at laypersons. However, no simple strategy could identify high quality websites in
general. For treating physicians, it is important to support patients in interpreting and ranking the vast quantity of
information.
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Background
Prostate cancer is the most commonly diagnosed cancer
in the male population worldwide [1]. Radiotherapy for
localized prostate cancer remains one of the mainstays
among treatment approaches. Other fields of application
are biochemical recurrences after prostatectomy, postoper-
ative radiotherapy in high-risk situations and palliative set-
tings e.g. painful bone metastases [2, 3]. As most patients
do not have personal experiences with radiotherapy, a lack
of information on risks and benefits is immanent. A recent
Canadian survey revealed that more than 90% of men with
newly diagnosed prostate cancer prefer to either play an
active or collaborative role in treatment decision-making
[4]. Thus, gaining valid medical information before initiat-
ing treatment seems essential for these patients to improve
their decision-making.
Today, a significant number of patients with prostate
cancer [5, 6] and radiation oncology patients [7, 8]
utilize the Internet to obtain medical information. For
cancer patients in general, Castleton et al. reported
Internet utilization in approximately two thirds of pa-
tients [9]. However, the quality of online information for
patients with prostate cancer is variable [6, 10–12]. For
instance, Ilic et al. found the quality of websites on pros-
tate cancer screening to be highly variable but mostly of
poor standard [10]. Similarly, others found shortcomings
in quality and accuracy of Internet health information for
the special topic of prostate cancer and proton therapy
[11]. Noteworthy, Shaverdian et al. showed that 39% of pa-
tients who selected the Internet as their primary informa-
tion source reported their actual treatment experience to
be worse than expected. Patients who had initially
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gathered medical information by consulting their urolo-
gists, radiation oncologist or even other patients reported
a significantly better treatment experience [6]. On the
other hand, a recently published analysis revealed a high
rating in quality, accessibility and usability of websites on
prostate cancer in general [12].
To our knowledge, there is no current analysis of con-
sumer health information on the Internet for patients
with prostate cancer in need of a radiation therapy. In
order to close that gap, our goal was to evaluate websites
with the focus on prostate cancer and radiotherapy.
Methods
Website identification and selection
A complete list of analyzed and excluded websites is given
in Additional file 1 of the appendix. Identification and se-
lection of websites (English language) took place on August
22nd 2017 (9.00 a.m. CET). The keywords “prostate cancer”
and “radiotherapy” were entered in the search-engines
Google.com, Bing.com and Yahoo.com to emulate real user
experience. A second search was carried out on September
9th 2017 (9.00 a.m. CET) to reveal possible temporal
dynamics. The first 20 websites were subjected to further
evaluation as it is known that patients rarely browse
through further sites when searching the web [12–14]. To
simulate a laypersons view, we excluded websites from fur-
ther analysis when complete access was restricted by pass-
word, the websites only included personal experiences (e.g.
blogs, videos) or contained limited information on radio-
therapy (< one paragraph), as described by others [15, 16].
In detail, websites were excluded based on the following
criteria: advertisement only (n = 2), a focus on clinical trials
(n = 4), scientific articles (n = 20), newspaper articles (n = 2),
video (n = 2), denied access (n = 2) and PowerPoint presen-
tation (n = 1). The vast majority of excluded websites was
found using the search engines Bing.com and Yahoo.com.
For the Google search, only one website met the above ex-
clusion criteria.
After the subtraction of duplicate websites (i.e. re-
peated appearance in different search engines and time
points) a total number of 49 websites was subjected to
further evaluation (n = 39 first search, n = 10 second
search). Apart from HON code, JAMA benchmark cri-
teria, ALEXA rank and DISCERN score, the country of
origin and website operator were recorded for each web-
site additionally. The quality of websites was evaluated
by two investigators (SJ, LK) independently using the
validated tools described below. Discrepancies were dis-
cussed and a consensus was reached.
The DISCERN tool was originally developed and vali-
dated in 1998 at the University of Oxford, UK. The aim
was to analyze written medical information with 15
questions in terms of reliability and details on treatment
(score of 1–5 for each question) [17, 18]. Overall quality
was additionally rated by a 16th question in the DISCERN
Plus score. As described by Nghiem et al. the results were
rated from “excellent” to “very poor” [19]. This method-
ology was used in a similar way in a previous published
work of our study group [20]. The individual DISCERN
items used in our study are visualized in Table 1. Follow-
ing DISCERN scoring, the respective websites were fur-
ther analyzed by using HON code [21] and JAMA [22]
(tools, as outlined by us in detail earlier [20]. With the
ALEXA traffic tool (https://www.alexa.com/) popularity
and engagement characteristics of websites can be
assessed. It is a measure of how often a website is fre-
quented relative to all other sites on the web over the past
three months.
Statistical analyses
We performed statistical analysis using GraphPad Prism
7 (GraphPad Software Inc., La Jolla, CA, USA) employ-
ing Spearman correlation, linear regression analysis and
two-tailed non-parametric Wilcoxon-Mann-Whitney
test for group comparisons as described in a previous
published work of our study group in detail [20].
Results
First, we analyzed the consistency of our data (i.e. exclu-
sion rates, duplicate websites and temporal changes in
search rank). Web search results obtained via Google
seemed adequately directed at laypersons (one website
excluded) and were highly consistent, as no duplicate re-
sults occurred and only a single new webpage was evi-
dent within the 20 hits in our second search after three
weeks (Fig. 1A). In contrast, exclusion rates (n = 8 and
Table 1 DISCERN Plus instrument (modified according to
Borgmann et al.)
Question 1: Aim clear?
Question 2: Aim achieved?
Question 3: Relevant?
Question 4: Sources clear?
Question 5: Dates of sources?
Question 6: Balanced and unbiased?
Question 7: Additional information?
Question 8: Areas of uncertainty?
Question 9: Describe treatment?
Question 10: Benefits of treatments?
Question 11: Risks of treatment?
Question 12: No treatment?
Question 13: Quality of life?
Question 14: Treatment choices?
Question 15: Shared decision-making?
Question 16: Overall quality?
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25) and the incidence of double hits (n = 8 and 10) and
of novel search results/ranks (n= 10 and 14, Fig. 1B, C) were
higher when Bing and Yahoo were employed, respectively.
Overall, the quality of information on websites about
prostate cancer and radiotherapy was good, with a mean
DISCERN Plus score of 55.1 ± 10.0, 51.8 ± 10.3 and 50.7
± 10.1 for Google, Yahoo and Bing, respectively. The
scores ranged from a minimum of 34 to a maximum of
74. 13% of all websites were rated as excellent, 31, 48
and 8% as good, fair and poor, respectively. No website
was rated as very poor. Figure 2 shows the item-based
results of the DISCERN score for the first search results
on August 22nd 2017 of all three search engines (n = 39
websites in total). The items with the lowest scores were
related to website content concerning sources/refer-
ences, up-to-dateness and quality of life issues (question
4–6 and 13, Table 1). The overall quality of websites
(DISCERN Plus score) was neither dependent on the
choice of search engines nor did we observe a significant
temporal change in quality (Fig. 3). The main categories
of websites retrieved from the first search were charity/
NGO sites (46%), followed by sponsored medical news
sites (28%), hospital/university sites (20%) and govern-
mental sites (6%). Websites operated by charity organi-
zations had significantly higher DISCERN Plus scores
(mean score: 55.5 ± 9.3) compared to hospital sites
Fig. 1 a-c: Google, Bing and yahoo search ranking at two different time points (black dots: august 22nd 2017, Open circles: September 9th 2017)
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(mean score: 47.3 ± 9.6, p < 0.042) and medical news sites
(mean score: 46.1 ± 6.1, p < 0.009), respectively. Most
websites originated in the USA (46%) followed by the
UK (33%), Australia/New Zealand (15%) and Canada
(6%). The JAMA benchmark criteria were fulfilled for all
four sections in 13%, for three, two and one section(s) in
13, 31 and 40%, respectively. One website did not fulfill
any of the JAMA criteria. Only 13% of all websites were
HON code certified. The median ALEXA global traffic
rank was 62,375 with a minimum of five and a max-
imum of 4,710,605.
Neither the JAMA benchmark criteria, the HON code
certification, the ALEXA traffic rank, the country of origin
(except slightly superior DISCERN score for UK websites
compared to USA websites, p < 0.033) nor the ranking
within the search results showed a significant association
with the respective DISCERN Plus score.
Of all analyzed websites, the vast majority had a clear
focus on radiotherapy for prostate cancer; four websites
provided only information for radiotherapy in general.
All analyzed websites had a focus on curative teletherapy
(i.e. definitive radiotherapy to the prostate or to prostatic
bed in a postoperative or salvage setting), 76, 51 and
22% of all websites mentioned brachytherapy, active sur-
veillance and palliative radiotherapy (i.e. radiotherapy to
other sites than the prostate or prostatic bed, e.g. bone
metastases), respectively. In 57% the procedure of radio-
therapy starting from first preparation, daily treatment
and aftercare was described in detail. Special radiation
techniques like “hypo-fractionation”, “Intensity modu-
lated Radiotherapy (IMRT)”, “Image guided Radiother-
apy (IGRT)” and “proton therapy” were mentioned in
37, 72, 27 and 31% of all analyzed websites, respectively.
Discussion
In recent years, the Internet has gained importance as a
source for health-related information. Several study
groups confirmed this fact in patients with oncological
diseases in general [9, 23], as well as for patients with
gynecologic cancers [24], breast cancer [19, 20], colorec-
tal cancer [25], bladder cancer [26], laryngeal cancer [27]
and prostate cancer [12] in particular. The increasing
amount of data published within the last two years high-
lights its clinical relevance.
For prostate cancer in particular there is a high need
for information because several treatment strategies
exist. Radiotherapy represents a major component for
the management of this oncologic entity. Thus, we
Fig. 2 Combined (n = 39 from Google, Bing and Yahoo) box and
whiskers (min to max) analysis of the individual DISCERN Plus score
items of the first search (mean indicated by +)
Fig. 3 Mean total DISCERN score for the three search engines at
two different time points
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performed an evaluation of websites addressing informa-
tion on prostate cancer and radiotherapy. The first 20
websites were subjected to further evaluation as it is
known that patients rarely browse through further sites
when searching the web [13]. Ngyuen et al. showed that
72% of the patients even restricted their search to 1–5
websites only [14]. In a study of Borgmann et al. the list
of evaluated websites was limited to 10 sites [12].
Overall, we found a good quality of information on ana-
lyzed websites according to the validated DISCERN Plus
score (for Google search: mean DISCERN Plus score: 55.1
± 10.0). Our results are in concordance with findings from
studies analyzing website quality of other cancer entities,
returning a mean DISCERN Plus score of 50 [27], 52 [25],
42 [28] and 42 [20], respectively. Notwithstanding, the
only other comparable study evaluating websites with gen-
eral information on prostate cancer, obtained higher DIS-
CERN Plus scores (mean 77) [12]. Taken together,
websites with information on prostate cancer seem to be
of slightly better quality compared to websites covering
other cancer entities. A potential reason why the web
search by Borgmann et al. returned webpages of higher
quality might be associated with the use of a more general
and popular search term. This is reflected by a lower
ALEXA traffic rank for prostate cancer sites in general
(median ALEXA traffic rank in the study of Borgmann et
al.: 2718) compared to our focus on radiotherapy and
prostate cancer (median ALEXA traffic rank: 62375). In
our study, webpage quality (DISCERN Plus score 2.14 ±
1.03) of less frequently visited websites (n = 14, ALEXA
traffic rank < 62,375) was not significantly different from
more frequently visited sites (n = 15, ALEXA traffic rank
> 62,375, DISCERN Plus score 1.67 ± 0.98). We did not
find an association of ALEXA traffic rank and superior
DISCERN score (data not shown).
In our analysis only 13% of websites were HON code
certified. Most other studies evaluating websites on can-
cer entities in general found higher certification rates
ranging from 20 to 38% [12, 19, 20, 26, 29–31]. The vast
majority of these studies showed that a higher HON
code certification was not necessarily accompanied by a
better content quality, as determined by the DISCERN
Plus score. Borgmann et al. presumed a lower HON
code certification frequency for websites on more spe-
cific topics, e.g. prostate cancer and radical prostatec-
tomy. This phenomenon could also account for the low
number of HON code certified websites in our study,
which is in concordance with findings by the study
group of Alkhateeb indicating 17% of HON code certifi-
cation in their focused web search on prostate cancer
and surgery [32].
The websites operated by charity organizations were of
superior quality concerning the DISCERN score com-
pared to hospital sites and sponsored medical news sites.
In line with this finding, Liebl et al. also found websites
of non-profit providers and self-help groups of superior
quality compared with profit-driven websites for cancer
patients in general [33]. Moreover, an earlier analysis of
our study group also revealed better results for hospital
and NGO websites compared to sponsored medical
news sites for webpages with information on breast can-
cer [20]. Thus, currently non-commercial sites should be
preferentially recommended to patients seeking informa-
tion on prostate cancer and radiotherapy.
No significant differences in the DISCERN Plus score,
JAMA benchmark criteria and HON code certification
were found between the three search engines (data not
shown). Search results obtained via Google were greatly
directed at laypersons and showed a high grade of
consistency (i.e. exclusion rates, duplicate websites and
temporal changes in search rank), in contrast to the
other search engines. These properties might render
Google a reliable choice for laypersons searching for in-
formation on prostate cancer and radiotherapy.
Interestingly, a large percentage of analyzed websites
provided information on modern radiotherapy tech-
niques like IMRT (72%). Also, websites mentioned
brachytherapy in the setting of curative treatment in
76% and the possibility of no treatment (active surveil-
lance) in 51%. Despite the well-balanced information on
modern treatment options for localized disease, we
found a significant lack of information on palliative
radiotherapy, which was only mentioned by 22% of
websites.
Limitations
One has to be aware that besides the influence of tem-
poral changes, internet search results may vary based on
e.g. the choice of search engine, search term, search date
and country of origin settings within the search engine.
However, within Google.com, no substantial differences
in search results were observed using different search
terms (e.g. “radiation” or “radiation therapy” instead of
“radiotherapy”) or countries of origin (data not shown).
Websites with complete access restricted by password,
websites with personal experiences only (e.g. blogs, videos)
or with limited information on radiotherapy (< one para-
graph), newspaper articles and PowerPoint presentations
were excluded from further analysis. We are aware of the
fact that those sources may also contain meaningful infor-
mation for prostate cancer patients. However, the exclusion
was executed to apply the above-mentioned tools in order
to standardize evaluation and to preserve comparability.
This was handled similar in other publications [15, 16].
Conclusion
Websites on radiotherapy and prostate cancer directed
at laypersons have the potential to sufficiently inform
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patients about general treatment options. The fact that
we were unable to find a simple strategy for the identifi-
cation of high-quality websites (i.e. HON code certifica-
tion, JAMA benchmark criteria, ALEXA ranking,
different search engines or country of origin and DIS-
CERN Plus score) emphasizes the responsibility of the
treating physicians to interpret and rank the vast quan-
tity of information.
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